Full Text Journal Articles by
Author Blase N Polite

Advertisement

Find full text journal articles






Facilities that service economically advantaged neighborhoods perform surgical metastasectomy more often for patients with colorectal liver metastases.

Abhineet Uppal, Fabrice Smieliauskas, Manish R Sharma, Steven B Maron, Blase N Polite, Mitchell C Posner, Kiran Turaga,

BACKGROUND:Metastasectomy of isolated colorectal liver metastases (CRLM) requires significant clinical expertise and may not be readily available or offered. The authors hypothesized that hospitals that treat a greater percentage of patients from higher income catchment areas are more likely to perform metastasectomies regardless of patient or tumor characteristics. METHODS:Using the ... Read more >>

Cancer (Cancer)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Opaque Results of Federal Price Transparency Rules and State-Based Alternatives.

Sheetal M Kircher, Trevor J Royce, Deep Upadhyay, Blase N Polite,

J Oncol Pract (Journal of oncology practice)
[2019, 15(9):463-464]

Cited: 0 times

View full text PDF listing >>



Advertisement

Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing.

Smita S Joshi, Daniel V T Catenacci, Theodore G Karrison, Jaclyn D Peterson, Mark M Zalupski, Amikar Sehdev, James Wade, Ahad Sadiq, Vincent J Picozzi, Andrea Amico, Robert Marsh, Mark F Kozloff, Blase N Polite, Hedy L Kindler, Manish R Sharma,

PURPOSE:5-Fluorouracil (5-FU)/leucovorin, irinotecan, and nab-paclitaxel are all active agents in gastrointestinal cancers; the combination, FOLFIRABRAX, has not been previously evaluated. UDP Glucuronosyltransferase 1A1 (UGT1A1) clears SN-38, the active metabolite of irinotecan. UGT1A1*28 polymorphism reduces UGT1A1 enzymatic activity and predisposes to toxicity. We performed a trial to assess the safety and ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2019, :]

Cited: 0 times

View full text PDF listing >>



Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.

Brendan J Guercio, Sui Zhang, Fang-Shu Ou, Alan P Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Bert H O'Neil, James E Shaw, Blase N Polite, Howard S Hochster, James N Atkins, Richard M Goldberg, Kaori Sato, Kimmie Ng, Erin Van Blarigan, Robert J Mayer, Charles D Blanke, Eileen M O'Reilly, Charles S Fuchs, Jeffrey A Meyerhardt,

PURPOSE:Regular physical activity is associated with reduced risk of recurrence and mortality in patients with nonmetastatic colorectal cancer. Its influence on patients with advanced/metastatic colorectal cancer (mCRC) has been largely unexplored. PATIENTS AND METHODS:We conducted a prospective cohort study nested in Cancer and Leukemia Group B (Alliance)/SWOG 80405 (ClinicalTrials.gov identifier: ... Read more >>

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2019, 37(29):2620-2631]

Cited: 0 times

View full text PDF listing >>



Ensuring Equity and Justice in the Care and Outcomes of Patients With Cancer.

Blase N Polite, Abbe R Gluck, Otis W Brawley,

JAMA (JAMA)
[2019, 321(17):1663-1664]

Cited: 0 times

View full text PDF listing >>



State of Cancer Care in America: Reflections on an Inaugural Year.

Blase N Polite, Jerome E Seid, Morganna Freeman, Laura A Levit, M Kelsey Kirkwood, Caroline Schenkel, Suanna S Bruinooge, Richard L Schilsky,

J Oncol Pract (Journal of oncology practice)
[2019, 15(4):163-165]

Cited: 0 times

View full text PDF listing >>



Investigation of a multimedia, computer-based approach to improve knowledge, attitudes, self-efficacy, and receptivity to cancer clinical trials among newly diagnosed patients with diverse health literacy skills.

Blase N Polite, Toni M Cipriano-Steffens, Chuanhong Liao, Edward L Miller, Nicole L Arndt, Elizabeth A Hahn,

BACKGROUND:Enrollment in therapeutic cancer trials remains low, and is especially challenging for patients with low health literacy. The authors tested an interactive technology designed for patients with diverse health literacy skills with the aim of improving patient receptiveness, willingness, knowledge, self-efficacy, and positive attitudes regarding clinical trials. METHODS:Patients presenting for ... Read more >>

Cancer (Cancer)
[2019, 125(12):2066-2075]

Cited: 0 times

View full text PDF listing >>



Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.

Scott K Sherman, Joel J Lange, Fadi S Dahdaleh, Rahul Rajeev, T Clark Gamblin, Blase N Polite, Kiran K Turaga,

Importance:Unregulated drug prices increase cancer therapy costs. After induction chemotherapy, patients with metastatic colon cancer can receive maintenance capecitabine and bevacizumab therapy based on improved progression-free survival, but whether this treatment's cost justifies its benefits has not been evaluated in the United States. Objective:This study sought to determine the influence ... Read more >>

JAMA Oncol (JAMA oncology)
[2019, 5(2):236-242]

Cited: 0 times

View full text PDF listing >>



A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.

Manish R Sharma, Smita S Joshi, Theodore G Karrison, Kenisha Allen, Grace Suh, Robert Marsh, Mark F Kozloff, Blase N Polite, Daniel V T Catenacci, Hedy L Kindler,

BACKGROUND:FOLFIRINOX (5-fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) is an effective but toxic therapy for pancreatic cancer. UGT1A1 (UDP glucuronosyltransferase 1A1) eliminates the active metabolite of irinotecan. Polymorphisms reduce UGT1A1 activity, leading to toxicity. The primary objective was to determine the dose-limiting toxicity (DLT) rate in cycle 1 of modified FOLFIRINOX (mFOLFIRINOX) ... Read more >>

Cancer (Cancer)
[2019, 125(10):1629-1636]

Cited: 2 times

View full text PDF listing >>



Engaging Patients in Value-Based Cancer Care: A Missed Opportunity.

S Yousuf Zafar, Blase N Polite, Mark McClellan,

JAMA Oncol (JAMA oncology)
[2018, 4(11):1479-1480]

Cited: 0 times

View full text PDF listing >>



Obstruction predicts worse long-term outcomes in stage III colon cancer: A secondary analysis of the N0147 trial.

Fadi S Dahdaleh, Scott K Sherman, Elizabeth C Poli, Janani Vigneswaran, Blase N Polite, Manish R Sharma, Daniel V Catenacci, Steven B Maron, Kiran K Turaga,

BACKGROUND:Patients with colon cancer often present with obstruction. Large series have reported obstruction among the high-risk features, yet prospective data on its specific prognostic influence are lacking. We hypothesized that obstruction is an independent risk factor for poor prognosis in patients with stage III colon cancer. METHODS:N0147 was a trial ... Read more >>

Surgery (Surgery)
[2018, 164(6):1223-1229]

Cited: 0 times

View full text PDF listing >>



Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial.

Michael R Marco, Lihong Zhou, Sujata Patil, Jorge E Marcet, Madhulika G Varma, Samuel Oommen, Peter A Cataldo, Steven R Hunt, Anjali Kumar, Daniel O Herzig, Alessandro Fichera, Blase N Polite, Neil H Hyman, Charles A Ternent, Michael J Stamos, Alessio Pigazzi, David Dietz, Yuliya Yakunina, Raphael Pelossof, Julio Garcia-Aguilar, ,

BACKGROUND:Adding modified FOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) after chemoradiotherapy and lengthening the chemoradiotherapy-to-surgery interval is associated with an increase in the proportion of rectal cancer patients with a pathological complete response. OBJECTIVE:The purpose of this study was to analyze disease-free and overall survival. DESIGN:This was a nonrandomized phase II ... Read more >>

Dis. Colon Rectum (Diseases of the colon and rectum)
[2018, 61(10):1146-1155]

Cited: 4 times

View full text PDF listing >>



The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey.

M Kelsey Kirkwood, Amy Hanley, Suanna S Bruinooge, Elizabeth Garrett-Mayer, Laura A Levit, Caroline Schenkel, Jerome E Seid, Blase N Polite, Richard L Schilsky,

PURPOSE:To describe the US hematology and medical oncology practice landscape and to report findings of the sixth annual ASCO Oncology Practice Census survey. PARTICIPANTS AND METHODS:ASCO used Medicare Physician Compare data to characterize oncology practices in the United States. Practice size, number of care sites, and geographic distribution were determined. ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2018, 14(7):e412-e420]

Cited: 8 times

View full text PDF listing >>



A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Amikar Sehdev, Theodore Karrison, Yuanyuan Zha, Linda Janisch, Michelle Turcich, Ezra E W Cohen, Michael Maitland, Blase N Polite, Thomas F Gajewski, Ravi Salgia, Navin Pinto, Marc B Bissonnette, Gini F Fleming, Mark J Ratain, Manish R Sharma,

BACKGROUND:Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor. Metformin may potentiate mTOR inhibition by sirolimus while mitigating its adverse effects. We conducted a pilot study to test this hypothesis. METHODS:Patients with advanced solid tumor were treated with sirolimus for 7 days followed by randomization to either sirolimus with metformin ... Read more >>

Cancer Chemother. Pharmacol. (Cancer chemotherapy and pharmacology)
[2018, 82(2):309-317]

Cited: 1 time

View full text PDF listing >>



A New Look at the State of Cancer Care in America.

Blase N Polite, Jerome E Seid, Laura A Levit, M Kelsey Kirkwood, Caroline Schenkel, Suanna S Bruinooge, Stephen S Grubbs, Deborah Y Kamin, Richard L Schilsky,

J Oncol Pract (Journal of oncology practice)
[2018, 14(7):397-399]

Cited: 1 time

View full text PDF listing >>



Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.

Rebecca Wellmann, Brittany A Borden, Keith Danahey, Rita Nanda, Blase N Polite, Walter M Stadler, Mark J Ratain, Peter H O'Donnell,

BACKGROUND:Germline and tumor pharmacogenomics impact drug responses, but germline markers less commonly guide oncology prescribing. The authors hypothesized that a critical number of clinically actionable germline pharmacogenomic associations exist, representing clinical implementation opportunities. METHODS:In total, 125 oncology drugs were analyzed for positive germline pharmacogenomic associations in journals with impact factors ... Read more >>

Cancer (Cancer)
[2018, 124(14):3052-3065]

Cited: 1 time

View full text PDF listing >>



Impact on Oncology Practices of Including Drug Costs in Bundled Payments.

Jeffery C Ward, Laura A Levit, Ray D Page, John E Hennessy, John V Cox, Deborah Y Kamin, Suanna S Bruinooge, Ya-Chen Tina Shih, Blase N Polite,

INTRODUCTION:This analysis evaluates the impact of bundling drug costs into a hypothetic bundled payment. METHODS:An economic model was created for patient vignettes from: advanced-stage III colon cancer and metastatic non-small-cell lung cancer. First quarter 2016 Medicare reimbursement rates were used to calculate the average fee-for-service (FFS) reimbursement for these vignettes. ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2018, 14(5):e259-e268]

Cited: 3 times

View full text PDF listing >>



A Rules-Based Algorithm to Prioritize Poor Prognosis Cancer Patients in Need of Advance Care Planning.

Christine M Bestvina, Kristen E Wroblewski, Bobby Daly, Brittany Beach, Selina Chow, Andrew Hantel, Monica Malec, Michael T Huber, Blase N Polite,

BACKGROUND:Accurate understanding of the prognosis of an advanced cancer patient can lead to decreased aggressive care at the end of life and earlier hospice enrollment. OBJECTIVE:Our goal was to determine the association between high-risk clinical events identified by a simple, rules-based algorithm and decreased overall survival, to target poor prognosis ... Read more >>

J Palliat Med (Journal of palliative medicine)
[2018, 21(6):846-849]

Cited: 1 time

View full text PDF listing >>



Association of externalizing religious and spiritual beliefs on stage of colon cancer diagnosis among black and white multicenter urban patient populations.

Blase N Polite, Toni M Cipriano-Steffens, Fay J Hlubocky, Pascal Jean-Pierre, Ying Cheng, Katherine C Brewer, Garth H Rauscher, George A Fitchett,

BACKGROUND:This study explores whether externalizing religious and spiritual beliefs is associated with advanced-stage colon cancer at initial oncology presentation and whether this association is stronger for blacks than for whites. METHODS:Patients who had newly diagnosed, invasive colon cancer were recruited at 9 sites in the Chicago metropolitan area. Eligible patients ... Read more >>

Cancer (Cancer)
[2018, 124(12):2578-2587]

Cited: 0 times

View full text PDF listing >>



The Road From Theory to Reality: Illuminating the Complexity of Prospective Cancer Bundles.

Blase N Polite,

J Oncol Pract (Journal of oncology practice)
[2018, 14(2):59-61]

Cited: 0 times

View full text PDF listing >>



Blase Polite on How Disparities Research Must Move Into an Era of Action.

Blase N Polite,

Oncology (Williston Park, N.Y.) (Oncology (Williston Park, N.Y.))
[2017, 31(10):709-10, 717]

Cited: 0 times

View full text PDF listing >>



Examining racial disparities in colon cancer clinical delay in the Colon Cancer Patterns of Care in Chicago study.

Lindsey A Jones, Carol Estwing Ferrans, Blase N Polite, Katherine C Brewer, Ajay V Maker, Heather A Pauls, Garth H Rauscher,

PURPOSE:We explored a potential racial disparity in clinical delay among non-Hispanic (nH) Black and White colon cancer patients and examined factors that might account for the observed disparity. METHODS:Patients aged 30-79 years with a newly diagnosed colon cancer from 2010 to 2014 (n = 386) were recruited from a diverse sample of ... Read more >>

Ann Epidemiol (Annals of epidemiology)
[2017, 27(11):731-738.e1]

Cited: 0 times

View full text PDF listing >>



Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.

Blase N Polite, Lucile L Adams-Campbell, Otis W Brawley, Nina Bickell, John M Carethers, Christopher R Flowers, Margaret Foti, Scarlett Lin Gomez, Jennifer J Griggs, Christopher S Lathan, Christopher I Li, J Leonard Lichtenfeld, Worta McCaskill-Stevens, Electra D Paskett,

J. Clin. Oncol. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2017, 35(26):3075-3082]

Cited: 11 times

View full text PDF listing >>



Charting the Future of Cancer Health Disparities Research: A Position Statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.

Blase N Polite, Lucile L Adams-Campbell, Otis W Brawley, Nina Bickell, John M Carethers, Christopher R Flowers, Margaret Foti, Scarlett Lin Gomez, Jennifer J Griggs, Christopher S Lathan, Christopher I Li, J Leonard Lichtenfeld, Worta McCaskill-Stevens, Electra D Paskett,

Cancer Res. (Cancer research)
[2017, 77(17):4548-4555]

Cited: 3 times

View full text PDF listing >>



Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.

Blase N Polite, Lucile L Adams-Campbell, Otis W Brawley, Nina Bickell, John M Carethers, Christopher R Flowers, Margaret Foti, Scarlett Lin Gomez, Jennifer J Griggs, Christopher S Lathan, Christopher I Li, J Leonard Lichtenfeld, Worta McCaskill-Stevens, Electra D Paskett,

CA Cancer J Clin (CA: a cancer journal for clinicians)
[2017, 67(5):353-361]

Cited: 5 times

View full text PDF listing >>



Advertisement

Disclaimer
1.9939 s